The company is substantially improved the development of an innovative treatment for amyloid heart disease, employing Attruby. Initial clinical information suggests promising outcomes for individuals affected by this https://attruby183431.blogoscience.com/48886111/bridgebio-improves-cardiac-amyloidosis-treatment-with-the-therapy